As part of Premier’s Technology Breakthroughs Program, Osprey Medical, Inc. has been awarded a group purchasing agreement giving Premier’s ~4,000 U.S. hospitals access to purchase the DyeVert Plus Contrast Reduction System. Osprey Medical’s DyeVert Plus System is the only technology cleared by the U. S. Food & Drug Administration for contrast reduction and real-time monitoring of dye dose delivered to patients during a coronary or peripheral angiogram. Use of the DyeVert Plus System has resulted in a mean 40% contrast media (dye) volume reduction, which has been shown to be statistically significant and clinically meaningful.

Osprey Medical (ASX:OSP) is pleased to announce a collaboration with GE Healthcare on Osprey’s Be Kind to Kidneys™ campaign. The campaign aims to increase awareness of strategies to help address acute kidney injury (AKI) following normal heart imaging procedures (angiograms) in patients with chronic kidney disease (CKD). As part of the campaign, Osprey Medical and GE Healthcare will sponsor a number of educational programs and seminars for healthcare professionals on how to address the risk of AKI.

Analyst Coverage Disclaimer
Please note that any opinions, esimates or forecasts regarding Osprey Medical's performance made by analysts mentioned on this website are theirs alone and do not represent opinions, forecasts or predictions of Osprey Medical or its management. Osprey Medical does not by its reference to any analysts imply its endorsement of or concurrence with their information, conclusions, or recommendations. Information provided by analysts is subject to change, and Osprey Medical cannot guarantee its accuracy.